UPDATE : Monday, February 17, 2020
[Exclusive] Patent of osteoarthritis drug Invossa refused in Europe by Nam Doo-hyun 2018-10-30 16:04
CrystalGenomics to change molecular targeted therapy from injection to oral drug in trials by Nam Doo-hyun 2018-10-30 10:52
‘Foreign investors fear Korean botox sales decline in China’ by Nam Doo-hyun 2018-10-29 16:52
‘Bio Solution’s value to rise on arthritis cell therapy’ by Nam Doo-hyun 2018-10-25 16:30
Novartis struggles to restore sales of Alzheimer’s drug Exelon by Nam Doo-hyun 2018-10-25 11:04
Will synthetic biology be vital in smart therapeutics? by Nam Doo-hyun 2018-10-24 16:40
Biotech shares tank amid nosediving of Seoul stocks by Nam Doo-hyun 2018-10-24 11:35
Anticoagulant Lixiana outpaces Eliquis in Q3 prescriptions by Nam Doo-hyun 2018-10-23 16:10
‘Antibody drug developer AbClon noteworthy’ by Nam Doo-hyun 2018-10-22 14:49
'Superbug' fears bring antibiotics developers under spotlight by Nam Doo-hyun 2018-10-22 11:53
Bayer’s blood thinner wins broader indication for coronary artery disease by Nam Doo-hyun 2018-10-19 16:34
Dental implant firms anticipate sales growth in H2 by Nam Doo-hyun 2018-10-18 14:52
‘Korea needs to toughen crackdown on illegal brokers for medical tourism’ by Nam Doo-hyun 2018-10-17 15:28
Relaxing requirement for innovative drugmakers will benefit Samsung, SK’ by Nam Doo-hyun 2018-10-17 14:38
CrystalGenomics hopes to test new leukemia drug early next year by Nam Doo-hyun 2018-10-16 16:17
Bio stocks listed under ‘tech exception policy’ perform better by Nam Doo-hyun 2018-10-15 12:27
Anticipation grows for Lenvima as new liver cancer drug by Nam Doo-hyun 2018-10-11 11:44
‘Korea publishes many biotech papers but rarely links them to biz’ by Nam Doo-hyun 2018-10-10 16:35
More biotech stocks come in top 20 on KOSDAQ by Nam Doo-hyun 2018-10-10 11:20
‘Medytox performance depends on Chinese regulations on peddlers’ by Nam Doo-hyun 2018-10-08 16:59
Back to Top